

Prepared on 15 Oct 2025

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of the ILP sub-fund and complements the Product Summary.
- It is important to read the Product Summary before deciding whether to purchase the ILP sub-fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP sub-fund if you do not understand it or are not comfortable with the accompanying risks.

BlackRock Global Funds - World Healthscience Fund (invests in BlackRock Global Funds - World Healthscience Fund A2 SGD Hedged)

Product Type	ILP sub-fund ¹	Launch Date	14 March 2022
Units in the ILP sub-fund are Excluded Investment Products ²	No	Custodian	The Bank of New York Mellon SA/NV, Luxembourg Branch
Manager	BlackRock (Luxembourg) S.A.	Dealing Frequency	Generally every business day in Luxembourg
Capital Guaranteed	No	Expense Ratio as at 30 June 2025	1.78%
Name of Guarantor	N.A.		

SUB-FUND SUITABILITY

WHO IS THE SUB-FUND SUITABLE FOR?

The ILP sub-fund is only suitable for investors who:

- Seek to maximise total return and invest in a manner consistent with the principles of environmental, social and governance ("ESG") investing.
- Seek to invest in stocks of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology
- Are informed investors willing to adopt capital and income risk.

Further Information Refer to "Investment Objective, Policy and Strategy" of Underlying the Fund's Singapore Prospectus for further information on sub-fund suitability.

KEY FEATURES OF THE SUB-FUND

WHAT ARE YOU INVESTING IN?

- You are investing in a ILP sub-fund that feeds 100% into an Underlying Fund, a sub-fund of BlackRock Global Funds ("BGF").
- BGF is an open-ended investment company incorporated in Luxembourg and its home regulator is the Commission de Surveillance du Secteur Financier ("CSSF").
- Non-Distributing Shares do not pay dividends whereas Distributing Shares pay dividends. For Distributing (G), (R), (S), (T) and (Y) Shares (if available): (i) dividends may come from capital of the Underlying Fund; (ii) this may reduce capital and the potential for capital growth of the Underlying Fund, and (iii) similar to other Distributing Shares, there is no guarantee of payout and the dividends may rise or fall.

Company" and "The Funds" of the Underlying Fund's Singapore Prospectus for further information on features of subfund.

Refer to

"The

Investment Strategy

 The Underlying Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.

Refer to "Investment Objective, Policy and Strategy" and

¹ For ILP sub-fund that feed 100% into an underlying CIS fund, some of the information provided below could be similar to the underlying CIS fund.

² In order for units in the ILP sub-fund to be classified as Excluded Investment Products, the investment objectives and investment focus of the ILP sub-fund, and investment approach of the manager have to be stated in the product summary:

⁽a) to invest only in deposits or other Excluded Investment Products; and

⁽b) not to engage in securities lending or repurchase transactions for the ILP sub-fund.

The definition of "Excluded Investment Product" can be found in Annex 1 to the Notice on Recommendations on Investment Products [Notice No. FAA-N16] at https://www.mas.gov.sg/regulation/notices/notice-faa-n16



- The Underlying Fund may invest directly up to 20% of its total assets in the PRC by investing via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.
- The Underlying Fund may use derivatives for investment purposes and for the purposes of efficient portfolio management.
- The Underlying Fund's total assets will be invested in accordance with the ESG Policy, as outlined below and further described in the Singapore Prospectus: Companies are evaluated by the Investment Adviser based on their ability to manage the risks and opportunities ("IA") associated with ESG factors and their ability to strategically manage longer-term issues surrounding ESG and the potential impact this may have on a company's financial performance. The IA conducts enhanced analysis on all companies that it considers to have heightened ESG risks, higher carbon emissions and controversial business activities. In such circumstances, the IA may determine an engagement agenda for discussion with those companies in seeking to improve their ESG credentials. To undertake this analysis, the IA uses its fundamental insights and may use data provided by external ESG data providers, and proprietary models.

"Use of Derivatives and Securities Lending" of the Underlying Fund's Singapore Prospectus for further information on investment strategy of subfund.

Parties Involved

WHO ARE YOU INVESTING WITH?

- The Management Company is BlackRock (Luxembourg) S.A.
- The Management Company has delegated its investment management function of The Underlying Fund to one or more investment advisers within the BlackRock Group who may sub-delegate some of its/their functions to one or more sub-advisers within the BlackRock Group (as listed in paragraph 3.2 of the Singapore Prospectus).
- The Depositary is The Bank of New York Mellon SA/NV, Luxembourg Branch.
- The Singapore Representative is BlackRock (Singapore) Limited.

Refer to "The Company", "Management and Administration" and "Other Parties" of the Underlying Fund's Singapore Prospectus for further information on the roles and responsibilities of these entities.

KEY RISKS

WHAT ARE THE KEY RISKS OF THIS INVESTMENT?

The value of the ILP sub-fund may rise or fall. The following key risk factors may cause you to lose some or all of your investment:

Refer to "RISK FACTORS" of the Underlying Fund's Singapore Prospectus for further information on key risk of subfund.

Market and Credit Risks

The Underlying Fund may be subject to Currency Risks

- Foreign currency exchange rate movements are likely to influence the returns to investors in Singapore, hence investors may be exposed to exchange rate risks.
- For Hedged Share Classes, while The Underlying Fund attempts to hedge currency risks, there can be no guarantee that it will be successful in doing so.

The Underlying Fund may be subject to Emerging and Frontier Market Risks

 The Underlying Fund may invest in one or more emerging and frontier markets and may be subject to a higher than average volatility than investing in more developed markets due to greater political, tax, economic, social, foreign exchange, custodial, liquidity, regulatory or other risks.

The Underlying Fund may be subject to Foreign Investment Restrictions Risks

Some countries prohibit or restrict investment, or the repatriation of income, capital or the
proceeds from sale of securities. The Underlying Fund may incur higher costs investing in these
countries. Such restrictions may delay the investment or repatriation of capital of the
Underlying Fund.

The Underlying Fund may be subject to Limited Market Sectors Risks

The Underlying Fund's investments are concentrated in the healthcare, pharmaceuticals and
other healthscience sectors. This may subject The Underlying Fund to greater volatility and
more rapid cyclical changes than more broad-based investments.

The Underlying Fund may be subject to Equity Risks



• The values of equities fluctuate daily and can be influenced by many factors including issuer-specific factors and broader economic and political developments.

Liquidity Risks

The ILP sub-fund is not listed on the Singapore Exchange and you can redeem only on Business Days through Singapore Life Ltd. In respect of Singapore investors, there is no secondary market for the ILP sub-fund.

Product-Specific Risks

The Underlying Fund may be subject to Derivatives Risks

• The use of derivatives may expose the Underlying Fund to a higher degree of risk. Derivative contracts can be highly volatile and a relatively small market movement may have a potentially larger impact on derivatives than on standard bonds or equities. Leveraged derivative positions can hence increase the Underlying Fund's volatility. The Underlying Fund may sustain loss as a result of the failure of a derivatives counterparty to comply with the terms of the derivatives contract.

The Underlying Fund may be subject to ESG Investment Policy Risk

• The use of ESG criteria may affect the Underlying Fund's investment performance and, as such, the Underlying Fund may perform differently compared to similar funds that do not use such criteria.

The Underlying Fund may be subject to the risks of Securities Lending

• The Underlying Fund may engage in securities lending. As such, the Underlying Fund will have a credit risk exposure to the counterparties to any securities lending contract. The Underlying Fund's investments can be lent to counterparties over a period of time. A default by the counterparty combined with a fall in the value of the collateral below that of the value of the securities lent may result in a reduction in the value of the Underlying Fund.

The Underlying Fund may be subject to Smaller Capitalisation Companies Risks

• The Underlying Fund may invest in small cap companies. Such investments may have higher than average volatility and liquidity risks.

FEES AND CHARGES

WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?

Payable directly by you

There is currently no Switching Fee for fund switching. Sales and/or Surrender Charges may be applicable as described in the relevant Product Summary. However, Singapore Life Ltd. reserves the right to review and amend the Fees and Charges.

Payable by the Underlying Fund from invested proceeds

The Underlying Fund will pay the following fees (as a % of the Underlying Fund's NAV) to the Investment Manager, Depository and other parties:

Management Fee* 1.50% p.a. (a) Retained by Management Company (a) 40% to 100% of Management Fee (b) Paid by Management Company to (b) 0% to 60% of Management Fee Singapore distributors (trailer fee) **Administration Fee*** Currently up to 0.25% p.a. Custody safekeeping fees: From 0.0024% to **Depository Fees** 0.45% p.a. Transaction fees: From US\$5.50 to US\$124 per transaction **Securities Lending Fee** BlackRock The securities lending agent, Advisors (UK) Limited, receives remuneration amounting to 37.5% of the gross revenue from securities lending, with all direct and indirect costs borne out of BlackRock's share.

Refer to the Fees and Charges Section of the Product Summary for further information of the Fees and Charges of this investment.

^{*} The combined Management and Administration Fees may be increased to up to a maximum of 2.25% in total by giving Shareholders 3 months' prior notice.



VALUATIONS AND EXITING FROM THIS INVESTMENT

HOW OFTEN ARE VALUATIONS AVAILABLE?

All ILP sub-funds will be priced based on the frequency of the fund manager's pricing. The fund prices are updated daily and are available at Singapore Life Ltd.'s website at www.singlife.com.

HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?

- You can exit the ILP sub-fund by submitting a request for withdrawal or fund switching (i.e. switches) to Singapore Life Ltd.
- If your Policy is newly incepted, you may cancel the Policy by giving us written notice of cancellation provided that such notice of cancellation is received by Singapore Life Ltd. at its Registered Office within the free-look period, which is fourteen (14) days from the date on which you receive the Policy.
- Upon cancellation of the Policy, Singapore Life Ltd. will refund the premiums you paid (without interest) after deducting the expenses incurred in issuing the Policy. The refund will be made after we receive the original Policy for cancellation.
- If there has been a decline in the market value, we will deduct the amount necessary to reflect the change in market value. If there has been an increase in the market value following the date Singapore Life Ltd. accepts your request to cancel the Policy, we will not pay you for such increase or any gain.
- For subsequent withdrawal/surrender or fund switching, transaction requests will need to be received and accepted by Singapore Life Ltd.:
 - (a) before 12 noon (Singapore time) on a Business Day will be processed according to the Unit Prices of the relevant Funds and the exchange rates (if applicable) prevailing on the next appropriate Fund Valuation Date following the day Singapore Life Ltd. has accepted the request.
 - (b) after 12 noon (Singapore time) on a Business Day or on a non-business day will be considered as if received before 12 noon (Singapore time) on the following business day.
- The ILP sub-fund will have a single "dealing" price used for all switches and withdrawals/surrenders. There is no bid/offer spread.
- All ILP sub-funds will be priced based on the frequency of the fund manager's pricing policy. As Units are cancelled using a forward price, the unit price for all switching and withdrawal of units will not be available at the time of receiving your application.
- This cut-off time stated is correct as at the time of print. Singapore Life Ltd. reserves the right to change the cut-off time by giving you thirty (30) days' prior notice or any such shorter period of notice as Singapore Life Ltd. may agree with the relevant authorities.
- The Withdrawal Amount you will receive as part of a subsequent withdrawal is illustrated as follows: For a partial withdrawal request of 1000 units of an investment-linked fund.
 - Assuming the unit price of the fund is S\$1.50:

The amount payable to the policyholder will be S\$1500, which is calculated as 1000 units x S\$1.50.

CONTACT INFORMATION

HOW DO YOU CONTACT US?

Singapore Life Ltd.

4 Shenton Way, #01-01 SGX Centre 2, Singapore 068807

New address w.e.f. 29 Dec 2025:

5 Straits View, #01-18/19, Marina One The Heart, Singapore 018935

Hotline: 6827 9933

APPENDIX: GLOSSARY OF TERMS

Underlying Fund: BlackRock Global Funds – World Healthscience Fund A2 SGD Hedged

Refer to the Pricing of Units & Dealing Deadline, Fund Switching, Withdrawal/
Surrender and Free Look sections of the Product Summary for further information.